Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Genor Biopharma Holdings Temettü

Temettü kriter kontrolleri 0/6

Genor Biopharma Holdings does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-HK$1.02
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if 6998's dividends per share have been stable in the past.

Büyüyen Temettü: 6998 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Genor Biopharma Holdings Piyasaya Karşı Temettü Getirisi

6998 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (6998)	n/a
Pazarın Alt %25'i (HK)	3.1%
Pazarın En İyi %25'i (HK)	7.9%
Sektör Ortalaması (Biotechs)	1.0%
Analist tahmini (6998) (3 yıla kadar)	0%

Önemli Temettü: Şirket yakın zamanda herhangi bir ödeme bildirmediğinden 6998 şirketinin temettü getirisi, temettü ödeyenlerin en alttaki %25'lik kısmına göre değerlendirilemiyor.

Yüksek Temettü: Unable to evaluate 6998's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate 6998's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as 6998 has not reported any payouts.

Genor Biopharma Holdings Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

New minor risk - Shareholder dilution

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Genor Biopharma Holdings Limited Announces China National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)

New minor risk - Share price stability

Genor Biopharma Holdings Limited Announces Board Changes

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Consensus forecasts updated

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

JHBP (CY) Holdings Limited Submits a Clinical Trial Application to the Bellberry Human Research Ethics Committee in Australia

JHBP (CY) Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

JHBP (Cy) Holdings Limited Receives Drug Approvals from the National Medical Products Administration

JHBP (CY) Holdings Limited Appoints Han Shuhua as New Chief Scientist

New 90-day high: HK$23.00

JHBP (CY) Holdings Limited has completed an IPO in the amount of HKD 2.877144 billion.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin